Callan Family Office LLC Acquires New Shares in CVS Health Corporation $CVS

Key Points

• Callan Family Office LLC acquired 164,995 CVS Health shares during the second quarter, valued at approximately $17.1 million. Institutional investors collectively own 80.66% of the company.
• CVS Health reported quarterly EPS of $2.58, beating estimates of $1.87, while revenue reached $106.1 billion, up 7.3% year over year and above expectations.
• Analysts maintain a favorable outlook, with 22 Buy ratings and two Holds, an average “Moderate Buy” rating, and an average price target of $107.17. The company also pays a quarterly dividend of $0.665, yielding about 2.9% annually.

Callan Family Office LLC acquired a new position in CVS Health Corporation (NYSE:CVS - Free Report) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 164,995 shares of the pharmacy operator's stock, valued at approximately $17,069,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Blue Capital Inc. acquired a new stake in shares of CVS Health during the 2nd quarter worth about $602,000. Keating Financial Advisory Services Inc. acquired a new position in CVS Health in the second quarter valued at about $130,000. OneAscent Wealth Management LLC acquired a new position in CVS Health in the second quarter valued at about $206,000. OneAscent Family Office LLC purchased a new position in CVS Health during the second quarter worth about $222,000. Finally, OneAscent Financial Services LLC acquired a new stake in shares of CVS Health during the second quarter valued at about $658,000. Hedge funds and other institutional investors own 80.66% of the company's stock.

CVS Health Price Performance

Shares of CVS opened at $93.01 on Friday. CVS Health Corporation has a fifty-two week low of $69.51 and a fifty-two week high of $110.68. The firm's 50 day moving average price is $102.02 and its 200 day moving average price is $88.86. The company has a market cap of $118.96 billion, a P/E ratio of 24.61, a PEG ratio of 0.85 and a beta of 0.61. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.74.

CVS Health (NYSE:CVS - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 EPS for the quarter, beating the consensus estimate of $1.87 by $0.71. The company had revenue of $106.10 billion during the quarter, compared to analysts' expectations of $100.03 billion. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. The firm's revenue was up 7.3% compared to the same quarter last year. During the same quarter last year, the company posted $1.81 EPS. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. On average, research analysts forecast that CVS Health Corporation will post 8.02 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 23rd were issued a $0.665 dividend. The ex-dividend date was Thursday, July 23rd. This represents a $2.66 dividend on an annualized basis and a yield of 2.9%. CVS Health's dividend payout ratio (DPR) is 70.37%.

Analysts Set New Price Targets

Several brokerages have recently commented on CVS. Mizuho upped their price objective on shares of CVS Health from $110.00 to $115.00 and gave the stock an "outperform" rating in a report on Monday, June 8th. UBS Group lifted their target price on shares of CVS Health from $122.00 to $126.00 and gave the company a "buy" rating in a report on Thursday, August 6th. Sanford C. Bernstein upped their price target on CVS Health from $94.00 to $106.00 and gave the stock an "outperform" rating in a research note on Tuesday, May 12th. Barclays raised their price target on CVS Health from $106.00 to $108.00 and gave the stock an "overweight" rating in a research report on Thursday, August 6th. Finally, TD Cowen lifted their price objective on CVS Health from $105.00 to $110.00 and gave the company a "buy" rating in a research note on Monday, May 11th. Twenty-two research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $107.17.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source